TP53 mutations are frequent in IDH-mutant astrocytomas but unusual in oligodendroglioma and the clinical significance of TP53 mutations in oligodendroglioma are not well characterized. We reviewed genetically defined oligodendroglioma (i.e., IDH-mutant, whole-arm 1p/19q-codeleted diffuse glioma) cases...
Notwithstanding the established role ofTP53mutation in MPN transformation,TP53-mutant subclones are also present in 16% of chronic phase MPN (CP-MPN), and in most cases, this does not herald the development ofTP53-sAML (ref.15). However, little is known about the additional genetic and nonge...
Get the TP53 gene in an Expression-Ready Vector for your molecular biology studies by ordering a TP53 ORF Clone.
Everolimus reduces microvessel density (MVD) and lymphatic vessel density (LVD) in TP53 mutant HNSCC xenografts. Credit:Oncotarget(2023). DOI: 10.18632/oncotarget.28355 A new research paper was published inOncotarget, titled, "Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis ...
David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment strategies for TP53-mutant MDS and AML. David Sallman, MD A clinical trial evaluating duplex TP53 minimal residual disease (MRD)...
Using ZMC1 in human breast cancer cell lines expressing the zinc deficient p53, we demonstrate that loss of BRCA1 sensitizes cells to mutant p53 reactivation. Using murine breast cancer models withdeficiency, we demonstrate that ZMC1 significantly improves survival of mice bearing tumors harboring ...
David Sallman, MD, discusses using eprenetapopt and azacitidine in TP53-mutant myelodysplastic syndrome and acute myeloid leukemia post-allogeneic stem cell transplantation.Video Player is loading.This is a modal window. This video is either unavailable or not...
Mutant TP53 proteins are also reported to have gain-of-function properties that can contribute to tumour growth. Open questions Are the reported gain-of-function effects of mutant TP53 proteins really critical for the sustained growth and therapy resistance of malignant cells?
Mutant TP53 interacts with other proteins to produce gain-of-function properties that contribute to cancer metastasis. However, the underlying mechanisms are still not fully understood. Using immunoprecipitation and proximity ligation assays, we evaluate
Mutant TP53 interacts with other proteins to produce gain-of-function properties that contribute to cancer metastasis. However, the underlying mechanisms are still not fully understood. Using immunoprecipitation and proximity ligation assays, we evaluate